Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.

Author information

Affiliations

  • 1. Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
      Authors
    • Rassy EE 1
    • Bakouny Z 1
    • Haddad FG 1
    • Assi T 1
    • Kattan J 1
    (5 authors)
  • 2. Department of Urology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
      Authors
    • Aoun F 2
    (1 author)
  • 3. Department of Biostatistics, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
      Authors
    • Sleilaty G 3
    (1 author)

ORCIDs linked to this article

Immunotherapy, 22 Mar 2018, 10(8):657-663
https://doi.org/10.2217/imt-2017-0190 PMID: 29562804 

Abstract 

Aim

To determine which of the approved immune checkpoint inhibitors is the optimal treatment in metastatic urothelial bladder cancer.

Methods & materials

Only the pivotal Phase III trials of second-line metastatic urothelial bladder cancer were included in this network meta-analysis.

Results

This NMA included three pooled trials (NCT00315237, NCT02256436 and NCT02302807) of 1125 participants. Pembrolizumab was the only treatment with positive effect on overall survival compared with the best supportive care. The treatment discontinuation rates due to adverse events of the pembrolizumab and atezolizumab did not differ from that of the best supportive care. C onclusion: Our results confirmed the superiority of pembrolizumab in the management of metastatic urothelial bladder cancer.

Full text links 

Read article at publisher's site: https://doi.org/10.2217/imt-2017-0190

References 

Articles referenced by this article (23)

Show 10 more references (10 of 23)

Citations & impact 

Impact metrics

3
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/34716628
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/34716628

Article citations

Data 

Data behind the article

This data has been text mined from the article, or deposited into data resources.

Clinical Trials (3)

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.